Abstract
Despite a slightly increased mortality at all ages, the average lifespan of patients with rheumatoid disease is little reduced and the majority will suffer from their arthritis for at least twenty-five years.
The prevalence of this condition has been estimated to be about 2-3 per cent. This high figure conceals different patterns of disease. There are some patients who experience a brief illness with early remission and apparent recovery; in others, gradual functional deterioration over the years is punctuated by a series of remissions and relapses. The pattern of illness may, on the other hand, be progressive with a course that does not seem to be appreciably altered by drug therapy. There is also a minority of, mainly, elderly patients who develop a malignant form of disease with a particularly aggressive and disabling arthritis, leading rapidly to severe handicap.
Treatment should ideally take account of the likely outcome of the illness. For those with the most aggressive disease, powerful and potentially toxic drugs may be appropriate and even radiotherapy may be justified as a part of controlled studies. To give such treatments to a patient who may have been destined to recover however, would be unfortunate, especially as there may be a long-term risk of adverse effects.
Recent studies have shown that only a small proportion of patients prescribed second-line drugs remain on treatment with any one agent for more than four years; the figure may be as low as 15 per cent. A second disease-modifying drug, given following failure of the first, may fare even less well. For patients who show sustained improvement on such drugs, the benefits are unequivocal. This minority, however, must be weighed against the majority whose treatment has to be discontinued. Of the latter, approximately half will have stopped their drugs because of side-effects, which range from the unpleasant to the life-threatening. The remainder will have had to contend with repeated clinic visits and blood tests in order to receive treatment that is at best inefficacious and at worst, dangerous.
As Duthie has shown, functional capacity can be maintained in a majority of patients using a conservation rehabilitation regime without recourse to second line drugs. If we are to continue to use these agents it is imperative that we learn how to use them more efficiently. We must know what constitutes a good or a poor prognosis, who is likely to respond to what treatment and who is most likely to suffer side-effects from the drugs. At present we may be over-treating those with a good prognosis, whilst those with a poor outlook may still be receiving inadequate or inappropriate therapy.
Preview
Unable to display preview. Download preview PDF.
References
Ropes, M. W., Bennett, G. A., Cobb, S. et al. ‘1958 revision of diagnostic criteria for rheumatoid arthritis’, Bull. Rheum. Dis. 9 (1958) 175–6.
Proposed criteria for use in population studies’, in Kellgren, J. H., Jeffrey, M. R. and Ball, J. (eds) The Epidemiology of Chronic Rheumatism, vol. I ( Philadelphia: Davis, 1963 ) 324–6.
Cathcart, E. S. and O’Sullivan, J. B. ‘Rheumatoid arthritis in a New England town: a prevalence study in Sudbury, Massachusetts’, New Engl. J. Med. 282 (1970) 421–4.
National Centre for Health Statistics, Rheumatoid Arthritis in Adults, United States 1960–62 (Rockville Maryland: National Centre for Health Statistics, 1966) (Vital and health statistics, series II: data from the national health survey No. 17; DHEW Publication No. (HRA) 75–1297).
Lawrence, J. S. Rheumatism in Populations ( London: Heinemann, 1977 ).
Behrend, T., Lawrence, J. S., Behrend, H. et al. ‘Prevalence of rheumatoid arthritis in rural Germany’, Int. J. Epidemiol. 1 (1972) 153–6.
Kellgren, L. ‘Prevalence of rheumatoid arthritis in different geographical areas of Sweden’, Acta Rheum. Scand. 16 (1970) 293–303.
Report from the subcommittee on diagnostic criteria for rheumatoid arthritis’, in Bennett, P. H. and Wood, P. H. N. (eds) Population Studies of the Rheumatic Diseases ( Amsterdam: Excerpta Medica, 1968 ) 454–5.
Ibid.
See note 3.
O’Sullivan, J. B., Cathcart, E. S. ‘Prevalence of rheumatoid arthritis: follow-up evaluation of the effect of criteria on rates in Sudbury, Massachusetts’, Ann. Intern. Med. 76 (1972) 573–7.
Beall, G. and Cobb, S. ‘The frequency distribution of episodes of rheumatoid arthritis as shown by periodic examination’, J. Chron. Dis. 14 (1961) 291–310.
Short, C. L., Bauer, W., Reynolds, W. E. Course of disease before hospital admission in rheumatoid arthritis. A definition of the disease and a clinical description based on the numerical study of 293 patients and controls ( Cambridge: Harvard University Press, 1957 ) 222–39.
Duthie, J. J. R., Thompson, M., Weir, M. M. et al. ‘Medical and social aspects of the treatment of rheumatoid arthritis, with special reference to factors affecting prognosis’, Ann. Rheum. Dis. 14 (1955) 133–48.
Duthie, J. J. R., Brown, P. E., Knox, J. D. E. et al. ‘Course and prognosis in rheumatoid arthritis’, Ann. Rheum. Dis. 16 (1957) 411–24.
Duthie, J. J. R., Brown, P. E., Truelove, L. H. et al. ‘Course and prognosis in rheumatoid arthritis. A further report’, Ann. Rheum. Dis. 23 (1964) 193–203.
Jacoby, R. K., Jayson, M. I. V., Cosh, J. A. ‘Onset, early stages and prognosis of rheumatoid arthritis; a clinical study of 100 patients with eleven year follow-up’, Br. Med. J. ii (1973) 96–100.
See notes 13 and 16.
Sharp, J. T., Calkins, E., Cohen, A. S. et al. ‘Observations of rheumatoid arthritis, based on the course of 154 cases’, Medicine (Baltimore) 43 (1964) 41–58.
Otten, H. A. and Boerma, F. W. ‘Significance of Waaler-Rose test, streptococcal agglutination and anti-streptolysin titre in the prognosis of rheumatoid arthritis’, Ann. Rheum. Dis. 18 (1959) 24–8.
See note 17.
Fleming, A., Crown, J. M. and Corbett, M. ‘Prognostic value of early features in rheumatoid disease’, Br. Med. J. (1976) 1243–5.
Masi, A. T., Maldonaldo-Cocco, J. A., Kaplan, S. B. et al. ‘Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome’, Sem. Arthritis Rheum. 5 (1976) 299–326.
Feigenbaum, S. L., Masi, A. T. and Kaplan, S. B. ‘Prognosis in rheumatoid arthritis. A longitudinal study of newly diagnosed younger adults’, Am. J. Med. 66 (1979) 377–84.
See note 17.
Rasker, J. J. and Cosh, J. A. ‘Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis’, Ann. Rheum. Dis. 40 (1981) 115–20.
Cosh, J. A. and Rasker, J. J. ‘A 20-year follow-up of 100 patients with rheumatoid arthritis (RA)’, Ann. Rheum. Dis. 41 (1982) 317.
See note 13.
Bywaters, E. G. L., Curwen, M., Dresner, E. et al. ‘Ten-year follow-up of rheumatoid arthritis’, Lancet, 2 (1960) 1381.
See note 22.
Bums, T. M., Cahn, A. ‘The hand radiograph as a diagnostic discriminant between seropositive and seronegative “rheumatoid arthritis”: a controlled study’, Ann. Rheum. Dis. 42 (1983) 605–12.
See notes 16, 17 and 20.
Cats, A. and Hazevoet, H. M. ‘Significance of positive tests for rheumatoid factor in the prognosis of rheumatoid arthritis. A follow-up study’, Ann. Rheum. Dis. 29 (1970) 254–9.
See notes 16, 19 and 22.
Ragan, C. and Farrington, E. ‘The clinical features of rheumatoid arthritis’, J. Am. Med. Assoc. 181 (1962) 663–7.
See note 26.
See note 22.
See note 22.
See notes 16, 17, 20 and 33.
See note 23.
See notes 22 and 35.
Bywaters, E. G. L. and Dresner, E. ‘The prognosis in rheumatoid arthritis’, Quart. J. Med. 21 (1952) 463.
Buckland-Wright, J. C. ‘X-ray assessment of activity in rheumatoid disease’, Br. J. Rheumatol. 22 (1983) 3–10.
Stastny, P. ‘HLA-D typing in rheumatoid arthritis’, Arthritis Rheum. 20 (1977) 845–59.
Stastny, P. ‘Association of the B cell allo-antigen DRW-4 with rheumatoid arthritis’, New Engl. J. Med. 298 (1978) 869–71.
Panayi, G. S., Wooley, P. and Batchelor, J. R. ‘Genetic basis of rheumatoid disease: HLA antigens, disease manifestations and toxic reactions to drugs’, Br. Med. J. ii (1978).
Young, A., Jaraquemada, D., Awad, J. et al. ‘Association of HLA-DR4/ DW-4 and DR2/DW-2 with radiologic changes in a prospective study of patients with rheumatoid arthritis: preferential relationship with HLA-DW rather than HLA-DR specificities’, Arthritis Rheum. 27 (1984) 20–25.
Sjoblom, K. G., Saxne, T., Pettersson, H. et al. ‘Factors related the progression of joint destruction in rheumatoid arthritis’, Scand. J. Rheumatol. (Suppl. 45 ) (1982) 22.
Scott, D. L., Coulton, B. L., Chapman, J. H. et al. ‘The long-term effects of treating rheumatoid arthritis’, J. Roy. Coll. Phys. Lond. 17 (1983) 79–85.
Research Subcommittee of the Empire Rheumatism Council, ‘Gold therapy in rheumatoid arthritis: final report of a multicentre controlled trial’, Ann. Rheum. Dis. 20 (1961) 315–34.
Multicentre Trial Group, ‘Controlled trial of D-penicillamine in severe rheumatoid arthritis’, Lancet i (1973) 275–80.
Urowitz, M. B., Gordon, D. A., Smythe, H. A. et al. ‘Azathioprine in rheumatoid arthritis. A double-blind, cross-over study’, Arthritis Rheum. 16 (1973) 411–18.
Freedman, A. and Steinberg, V. L. ‘Chloroquine in rheumatoid arthritis. A double-blind trial of treatment for one year’, Ann. Rheum. Dis. 19 (1960) 243–50.
Cooperating Clinics Committee of the American Rheumatism Association, ‘A controlled trial of cyclophosphamide in rheumatoid arthritis’, New Engl. J. Med. 283 (1970) 883–9.
Iannuzzi, L., Dawson, N., Zein, N. et al. ‘Does drug therapy slow radiograph deterioration in rheumatoid arthritis?’, New Engl. J. Med. 309 (1983) 1023–8.
Sigler, J. W., Blum, G. B., Duncan, H. et al. ‘Gold salts in the treatment of rheumatoid arthritis’, Ann. Intern. Med. 80 (1974) 21–6.
Cooperating Clinics Committee of the American Rheumatism Association, ‘A controlled trial of gold salt therapy in rheumatoid arthritis’, Arthritis Rheum. 16 (1973) 353–8.
Luukainen, R. ‘Chrysotherapy in rheumatoid arthritis, with particular emphasis on the effect of chrysotherapy on radiographical changes and on the optimal time of initiation of therapy’, Scand. J. Rheumatol. 34 (Suppl.) (1980) 1–56.
See note 54.
Scott, D. L., Grindulis, K. A., Struthers, G. R. et al. ‘Progression of radiological changes in rheumatoid arthritis’, Ann. Rheum. Dis. 43 (1984) 8–17.
Pullar, T., Hunter, J. A. and Capell, H. A. ‘Does second-line therapy affect the radiological progression in rheumatoid arthritis?’, Ann. Rheum. Dis. 43 (1984) 18–23.
Ibid.
Joint Committee of the Medical Research Council and Nuffield Foundation, ‘A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis’, Ann. Rheum. Dis. 18 (1959) 173–88
Heroic treatment for non-malignant disease’, J. Am. Med. Assoc. 248 (1982) 1743–4.
Williams, I. A., Baylis, E. M. and Shipley, M. E. ‘A double-blind placebo-controlled trial of methylprednisolone pulse therapy in active rheumatoid disease’, Lancet, 31 July 1982, 237–40.
Liebling, M. R., Leib, E., McLaughlin, K. et al. ‘Pulse methylprednisolone in rheumatoid arthritis: a double-blind cross-over trial’, Ann. Intern. Med. 94 (1981) 21–6.
Ibid.
Pullar, T., Hunter, J. A. and Capell, H. A. ‘Sulphasalazine in rheumatoid arthritis: a double-blind comparison of sulphasalazine with placebo and sodium autothiomalate’, Br. Med. J. 287 (1983) 1102–4.
Neumann, V. C., Grindulis, K. A., Hubball, S. et al. ‘Comparison between penicillamine and sulphasalazine in rheumatoid: Leeds-Birmingham trial’, Br. Med. J. 287 (1983) 1099–02.
Kotzin, B. L., Strober, S., Engleman, E. G. et al. ‘Treatment of intractable rheumatoid arthritis with total lymphoid irradiation’, New Engl. J. Med. 305 (1981) 969–76.
Trentham, D. E., Belli, J. A., Anderson, R. J. et al. ‘Clinical and immunologic effects of fractionated total lymphoid irradiation in refractory rheumatoid arthritis’, New Engl. J. Med. 305 (1981) 976–82.
Field, E. H., Strober, S., Hoppe, R. T. et al. ‘Sustained improvement of intractable rheumatoid arthritis after total lymphoid irradiation’, Arthritis Rheum. 26 (1983) 937.
McCarty, D. J. and Carrera, G. F. ‘Intractable rheumatoid arthritis. Treatment with combined cyclophosphamide, azathioprine and hydroxychloropine’, J. Am. Med. Assoc. 248 (1982) 1718–23.
Srinivasan, R., Miller, B. L. and Paulus, H. E. ‘Long-term chrysotherapy in rheumatoid arthritis’, Arthritis Rheum. 22 (1979) 105–10.
Rosenthal, M. ‘Loss of efficacy of antirheumatic drugs in rheumatoid arthritis’, J. Rheumatol. 7 (1980) 586–7.
Rothermich, N. O., Philips, V. K., Bergen, W. et al. ‘Chrysotherapy: A prospective study’, Arthritis Rheum. 19 (1976) 1321–7.
Rothermich, N. O., Philips, V. K., Bergen, W. et al. ‘Follow-up study of chrysotherapy’, Arthritis Rheum. 22 (1979) 423.
Sambrook, P. N., Brown, C. D., Champion, G. D. et al. ‘Terminations of treatment with gold sodium thiomalate in rheumatoid arthritis’, J. Rheumatol. 9 (1982) 932–4.
Evers, A. E. and Sundstrom, W. R. ‘Second course gold therapy in the treatment of rheumatoid arthritis’, Arthritis Rheum. 26 (1983) 1071–5.
Webley, M. and Coomes, E. N. ‘An assessment of penicillamine therapy in rheumatoid arthritis and the influence of previous gold therapy’, J. Rheumatol. 6 (1979) 20–4.
Rothermich, N. O., Thomas, M. H., Phillips, V. K. et al. ‘Clinical trial of penicillamine in rheumatoid arthritis’, Arthritis Rheum. 24 (1981) 1473–8.
Kean, M. F., Dwosh, I. L., Anastassiades, T. P. et al. ‘The toxicity pattern of D-penicillamine therapy’, Arthritis Rheum. 23 (1980) 158–64.
Richter, J. A., Runge, L. A., Pinals, R. S. et al. ‘Analysis of treatment terminations with gold and anti-malarial compounds in rheumatoid arthritis’, J. Rheumatol. 7 (1980) 153–9.
Husain, Z. and Runge, L. A. ‘Treatment complications of rheumatoid arthritis with gold, hydroxychloroquine, D-penicillamine and levamisole’, J. Rheumatol. 7 (1980) 825–30.
Currey, H. L. F., Harris, J., Mason, R. M. et al. ‘Comparison of azathioprime, cyclophosphamide and gold in treatment of rheumatoid arthritis’, Br. Med. J. iii (1974) 763–6.
Dwosh, I. L., Stein, H. B., Hunter, T. et al. ‘Azathioprine in early rheumatoid arthritis: a comparison study with gold and chloroquine’, Arthritis Rheum. 20 (1977) 685–92.
Girdwood, R. H. ‘Death after taking medications’, Br. Med. J. i (1974) 501–4.
Davis, P. ‘Undesirable effects of gold salts’, J. Rheumatol. 5 (Suppl.) (1979) 18–24.
Phenylbutazone and oxyphenbutazone: time to call a halt’, Drug Therap. Bull. 22 (1984) 5–6.
Kay, A. G. L. ‘Myelotoxicity of D-penicillamine’, Ann. Rheum. Dis. 38 (1979) 232–6.
Whisnant, J. K., Pelkey, J. ‘Rheumatoid arthritis: treatment with azathioprime (IMURAN (R)) Clinical side-effects and laboratory abnormalities’, Ann. Rheum. Dis. 41 (Suppl.) (1982) 44–7.
Kinlen, L. J., Sheil, A. G. R., Peto, J. et al. ‘Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs’, Br. Med. J. ii (1979) 1461–6.
Kahn, M. F., Arlet, J., Bloch-Michel, H. et al. ‘Leucémies aiguës traitement par agents cytotoxiques en rhumatologies: 19 observations chez 2006 patients’, Nouv. Presse Med. 8 /17 (1979) 1393–7.
Allebeck, P., Ahlbohm, A. and Allander, E. ‘Increased morality among persons with rheumatoid arthritis, but where RA does not appear on the death certificate. Eleven years’ follow-up of an epidemiological study’, Scand. J. Rheumatol. 10 (1981) 301–6.
Allebeck, P. ‘Increased mortality in rheumatoid arthritis. The use of a medical information system for assessment of death risks’, Scand. J. Rheumatol. 11 (1982) 8–86.
Koota, K., Isomaki, H. and Mutou, O. ‘Death rate and causes of death in RA patients during a period of five years’, Scand. J. Rheumatol. 6 (1977) 241–4.
Isomaki, H. A., Hakulinen, T. and Joutsenlahti, V. ‘Excess risk of lymphomas, leukaemia and myeloma in patients with rheumatoid arthritis’, J. Chron. Dis. 31 (1978) 691–6.
Hazleman, B. L. and Da Silva, M. ‘The comparative incidence of malignant disease in rheumatoid arthritis exposed to different regimens’, Ann. Rheum. Dis. 41 (Suppl.) (1982) 12–17.
Urowitz, M. B., Smythe, H. A., Able, T. et al. ‘Long-term effects of azathioprine in rheumatoid arthritis’, Ann. Rheum. Dis. 41 (Suppl.) (1982) 18–22.
Kay, A. ‘EULAR register of patients on immunosuppressive drugs’, Ann. Rheum. Dis. 41 (Suppl.) (1982) 30–1.
Court-Brown, W. M. and Doll, R. Leukaemia and Aplastic Anaemia in Patients Irradiated for Ankylosing Spondylitis’, MRC Special Report Series No. 295 ( London: HMSO, 1957 ).
See note 70.
See note 26.
See note 94.
Abruzzo, J. L. ‘Rheumatoid arthritis and mortality’, Arthritis Rheum. 25 (1982) 1020–2.
Huskisson, E. C. ‘The side-effects of penicillamine therapy in rheumatoid arthritis’, J. Rheumatol. (Suppl. 7 ) (1981) 146–8.
Wooley, P. H., Griffin, J., Panayi, G. S. et al. ‘HLA-DR antigens and toxic reactions to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis’, New Engl. J. Med. 303 (1980) 30D - 2.
Bardin, T., Dryll, A., Debeyre, N. et al. ‘HLA system and side-effects of gold salts and D-penicillamine in the treatment of rheumatoid arthritis’, Ann. Rheum. Dis. 41 (1982) 599–601.
Meenan, R. F., Yelin, E. H., Nevitt, M. et al. ‘The impact of chronic disease. A socio-medical profile of rheumatoid arthritis’, Arthritis Rheum. 24 (1981) 544–9.
See note 3.
See note 73.
Sharp, J. T., Lidsky, M. D., Duffy, J. ‘Clinical responses during gold therapy for rheumatoid arthritis. Changes in synovitis, radiologically detectable erosive lesions, serum proteins and serologic abnormalities’, Arthritis Rheum. 25 (1982) 540–9.
Pinals, R. S., Massie, A. T. and Larsen, R. A. ‘Preliminary criteria for clinical remission in rheumatoid arthritis’, Arthritis Rheum. 24 (1981) 130815.
Fries, J. J. ‘Toward an understanding of patient outcome measurement’, Arthritis Rheum. 26 (1983) 697–704.
Fries, J. F. ‘The assessment of disability: from first to future principles’, Br. J. Rheumatol. 22 (Suppl.) (1983) 48–58.
Hurst, J. W. ‘Measuring the benefits and costs of medical care: the contribution of health status measurement’, Health Trends, 16 (1984) 16–19.
See note 14.
See notes 15 and 16.
Editor information
Editors and Affiliations
Copyright information
© 1984 D. H. Goddard and R. C. Butler
About this chapter
Cite this chapter
Price, T. (1984). Cost versus benefit: a treatment audit. In: Goddard, D.H., Butler, R.C. (eds) Rheumatoid Arthritis: The Treatment Controversy. Palgrave, London. https://doi.org/10.1007/978-1-349-08808-9_6
Download citation
DOI: https://doi.org/10.1007/978-1-349-08808-9_6
Publisher Name: Palgrave, London
Print ISBN: 978-0-333-41920-5
Online ISBN: 978-1-349-08808-9
eBook Packages: MedicineMedicine (R0)